Breaking News

Financial Report: Pfizer

August 7, 2014

Earnings drop 79% in the quarter

2Q Revenues: $12.8 billion (-2%)

2Q Earnings: $2.9 billion (-79%)

YTD Revenues: $24.1 billion (-5%)

YTD Earnings: $5.2 billion (-69%)

Comments: Global Vaccines revenue grew 14% operationally, with Prevnar revenue up 13% to $1.1 billion in the quarter. Global Oncology revenues increased 16% to $570 million, primarily driven by the continued strong uptake of Xalkori and Inlyta. Lyrica sales were up 15% to $1.3 billion in the quarter. Viagra sales were down 11% to $427 million. Consumer Healthcare revenues increased 14% to $912 million. Increased generic competition to several products and the end of some revenue-producing partnerships cut revenue by $850 million in the quarter.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks